Med (New York, N.Y.) · 2026
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis.
СтатьяNetwork Meta-AnalysisСистематический обзорСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsutsumi Tsubasa, Tang Nicole Shu Ying, Ng Cheng Han, Suzuki Hiroyuki, Syn Nicholas L, Sasikumar N Apoorva, Ho Glenn Jun Kit, Chua Damien, Tioh Jing Kai, Pramotedham Thanawin, Vigneshwaran Selvakumar, Low Peter Jin Sun, Moon Joon Ho, Young Dan Yock, Wong Vincent Wai-Sun, Zheng Ming-Hua, Le Roux Carel W, Schattenberg Jörn M, Huang Weiting Ting, Kendall Timothy J, Fallowfield Jonathan A, Chen Vincent L, Takahashi Hirokazu, Rinella Mary E, Siddiqui Mohammad Shadab, Noureddin Mazen, Sanyal Arun J, Muthiah Mark D, Kawaguchi Takumi
Аннотация
BACKGROUND: Metabolic-dysfunction-associated steatohepatitis has a rapidly expanding phase 2-3 drug pipeline, yet comparative evidence across mechanisms remains limited, and most trials are placebo controlled.
METHODS: We performed a systematic review and frequentist network meta-analysis of phase 2-3 randomized trials in adults with non-cirrhotic disease. Primary endpoints were (1) resolution of steatohepatitis without worsening of fibrosis, (2) at least one-stage improvement in fibrosis without worsening of steatohepatitis (both biopsy based), and (3) at least a 30% relative reduction in liver fat measured by magnetic resonance imaging-derived proton density fat fraction. Interventions were compared across mechanistic groups and ranked using network estimates.
FINDINGS: Sixty-four trials (12,787 participants) were included. Therapies targeting metabolic dysfunction and insulin sensitivity showed the most consistent benefits versus placebo (odds ratios 2.5-7.1) and the lowest failure rates across biopsy and imaging endpoints, whereas anti-inflammatory and anti-fibrotic agents showed more variable biopsy responses. Fibroblast growth factor 21 analogs and incretin-based multi-agonists ranked among the leading classes. Despite favorable relative effects, absolute non-response remained substantial: 35%-70% of treated participants did not meet prespecified biopsy endpoints, and biopsy placebo response rates were 11%-18%.
CONCLUSIONS: By benchmarking cross-class performance in a predominantly placebo-anchored network, these findings support metabolic therapies as a rational foundation for combination regimens spanning complementary mechanisms and highlight the need for more durable approaches to achieve clinically meaningful biopsy outcomes.
FUNDING: This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
METHODS: We performed a systematic review and frequentist network meta-analysis of phase 2-3 randomized trials in adults with non-cirrhotic disease. Primary endpoints were (1) resolution of steatohepatitis without worsening of fibrosis, (2) at least one-stage improvement in fibrosis without worsening of steatohepatitis (both biopsy based), and (3) at least a 30% relative reduction in liver fat measured by magnetic resonance imaging-derived proton density fat fraction. Interventions were compared across mechanistic groups and ranked using network estimates.
FINDINGS: Sixty-four trials (12,787 participants) were included. Therapies targeting metabolic dysfunction and insulin sensitivity showed the most consistent benefits versus placebo (odds ratios 2.5-7.1) and the lowest failure rates across biopsy and imaging endpoints, whereas anti-inflammatory and anti-fibrotic agents showed more variable biopsy responses. Fibroblast growth factor 21 analogs and incretin-based multi-agonists ranked among the leading classes. Despite favorable relative effects, absolute non-response remained substantial: 35%-70% of treated participants did not meet prespecified biopsy endpoints, and biopsy placebo response rates were 11%-18%.
CONCLUSIONS: By benchmarking cross-class performance in a predominantly placebo-anchored network, these findings support metabolic therapies as a rational foundation for combination regimens spanning complementary mechanisms and highlight the need for more durable approaches to achieve clinically meaningful biopsy outcomes.
FUNDING: This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.